Boxer Capital’s Array Biopharma Inc ARRY Stock Holding History

Boxer Capital’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-200,000	Closed	-$1.76M	–	32
2016 Q4	$1.76M	Hold	200,000	–	–	0.68%	17
2016 Q3	$1.35M	Buy	+200,000	New	+$774K	0.61%	22

Other funds holding ARRY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Boxer Capital's ARRY Position: Q1 2017 in Review

Boxer Capital sold out of Array Biopharma Inc (ARRY) in Q1 2017, closing a stake of 200,000 shares — an estimated $1.76M sold.

Boxer Capital first reported a position in ARRY in Q3 2016 and held it in 2 quarters. The position peaked at $1.76M in Q4 2016. 187 funds tracked by Wall St. Rank hold ARRY as of Q1 2017.

Boxer Capital reported no remaining Array Biopharma Inc position as of Q1 2017 after selling out during the quarter.
Boxer Capital sold 200,000 Array Biopharma Inc shares in Q1 2017, an estimated $1.76M.
Boxer Capital first reported a position in Array Biopharma Inc in Q3 2016 and held it in 2 quarters.
Boxer Capital's Array Biopharma Inc position peaked at $1.76M in Q4 2016.
187 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2017.

Based on Boxer Capital's 13F filing for Q1 2017, filed 15 May 2017.